Saturday 17 October 2026
Export MIRA’s income statement to Excel — free account
MIRA Pharmaceuticals, Inc.
MIRA Healthcare Drug Manufacturers General
In the quarter to June 2026, EPS grew 66.7% and free cash flow fell 50.8%, each against the same quarter a year earlier.
0.63
0.03
−4.55%
Follow MIRA
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
Current Ratio |
0.04 | 2.57 | 0.36 | 8.70 | 3.99 | 15.75 |
Net Debt/EBITDA |
(1.28) | 1.17 | 0.03 | 0.54 | 0.35 | 1.05 |
Debt/Assets |
318.02% | 8.74% | 15.51% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(1.45) | 0.13 | (0.22) | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.00 | 0.63 | 0.79 | 0.38 | 0.71 | 0.15 |
Capex/Depreciation |
— | — | — | 0.00 | — | — |
Interest Coverage |
(338.00) | (176.41) | (684.26) | (2.47) | 48.39 | — |
| 0.00% | (197.93%) | (847.73%) | (634.30%) | (238.90%) | (508.28%) | |
| 0.00% | (128.65%) | (335.04%) | (413.86%) | (199.93%) | (456.59%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
78.25% | (126.85%) | 806.10% | (278.65%) | (362.81%) | (308.99%) |
Average Days of Receivables |
— | — | — | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
0.00 | (0.09) | (0.32) | (0.33) | (0.36) | (0.20) |
Cash per Share |
0.00 | 0.19 | 0.02 | 0.33 | 0.18 | 0.47 |
Shareholders Equity per Share |
0.00 | 0.15 | (0.03) | 0.31 | 0.14 | 0.44 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.15 | (0.03) | 0.31 | 0.14 | 0.44 |
Free Cash Flow |
(0.07) | (1.38) | (5.60) | (4.53) | (5.56) | (4.66) |
Working Capital |
(0.09) | 1.72 | (0.88) | 4.30 | 2.16 | 10.36 |
Net Current Asset Value |
(0.09) | 1.72 | (0.96) | 4.30 | 2.16 | 10.36 |
| Other line items | ||||||
Quick Ratio |
0.04 | 2.57 | 0.26 | 8.27 | 3.92 | 15.71 |
Depreciation/Fixed assets |
— | — | 0.00 | 0.00 | — | — |
Cash ROIC |
(216.56%) | (25.66%) | 4,999.82% | (50.49%) | (110.49%) | (21.76%) |
Accounts Payable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
0.00 | (0.09) | (0.32) | (0.33) | (0.36) | (0.20) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | — | — | 0.73 | 0.63 | 0.43 |
Average Assets |
— | 1.69 | 2.11 | 2.90 | 3.93 | 7.01 |
Average Common Equity |
— | 1.10 | 0.83 | 1.89 | 3.29 | 6.30 |
Columns are period end dates